Associations of SGLT2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone Therapy

Ethics Approval

This is an observational study. The need for Institutional Review Board (IRB) approval was waived by Lahey Clinic IRB due to the use of deidentified data for the analysis. The study findings are reported per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for cohort studies.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Conflict of Interest

EK is supported in part by NIH/NCI 1RO1HL157273 and by CPRIT RP200381. AD is supported in part by the Ting Tsung and Wei Fong Chao Distinguished Chair and is a consultant for Bayer. JB is consultant for Abbott, American Regent, Amgen, Applied Therapeutic, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CVRx, Cytokinetics, Edwards, Element Science, Innolife, Impulse Dynamics, Imbria, Inventiva, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Roche, Sequana, SQ Innovation, and Vifor. AWH is consultant for Janssen, Intellisphere, Exelixis, has received honoraria from Medscape, Binaytara Foundation, travel support from Dava Oncology, and institutional funding from Bayer and Eisai. The remaining authors have nothing to disclose.

留言 (0)

沒有登入
gif